Navigation Links
New Aid for AIDS - ICAP Ocean Tomo Announces Auction of a Keystone Patent for Cell Therapy Use of Modified Red Blood Cells for Treating Viral Diseases
Date:3/14/2011

CHICAGO, March 14, 2011 /PRNewswire/ -- Developed by inventor Lawrence F. Glaser and represented by ICAP Ocean Tomo, this technology will be auctioned off at ICAP Ocean Tomo's Spring 2011 Live IP Auction on March 31, 2011 in New York City.

(Logo:  http://photos.prnewswire.com/prnh/20100614/CG20517LOGO)

Key Characteristics & Benefits

This patent discloses the following:

  • The use of genetically modified erythrocytes/red blood cells (RBC) for treating and preventing viral infections. Modified cells can also be generated through non-recombinant low-cost means, such as with ghosting techniques using mature patient or donor cells.
  • A desired protein receptor/coreceptor may be introduced into precursor cells using a gene transfer technique, such as transfection, transduction, and gene gun. These modified precursor cells can then be cultured in a suitable environment to generate the desired erythrocyte having a specific protein receptor complex, used as a trap for treating a target viral infection.
  • The disclosed erythrocytes comprise HIV receptors capable of mediating HIV entry into the modified cells. When these modified erythrocytes are administered to an HIV+ patient, the erythrocytes attract and absorb HIV, uncloaking each viral particle preventing further viral infection through direct depletion of viral load.
  • The entrapped virus is subsequently degraded and deactivated within the erythrocytes, assuring entrapment.  Red Cells are eliminated through the natural cycle, Erythrophagocytosis, shown in research studies to completely disintegrate any payload.
  • The modified erythrocytes can be prepared from the erythrocyte precursor cells isolated from peripheral blood, bone marrow, umbilical cord blood, or any other suitable source within the human body.  The non-recombinant method can be created from mature enucleated red cells.
  • The disclosed erythrocyte receptors can be made with different protein sequences for treating and preventing various viral infections and other targets, or used preemptively to track any meaningful predictive drift in the target.
  • Cells of the invention can be manufactured and sold now, for use as a new tool in labs, adding in other distinct features to enhance the reporter function.  
  • The concept may cross over into other disease modalities, such as cancer or immune regulation.

Market Potential

This lot should be of interest to cell therapy organizations, biotechnology organizations, gene therapy organizations, healthcare service providers, pharmaceutical/drug manufacturers, and entities involved in medical research.

  • The global HIV drug market was worth $9.3 billion in 2007 and is expected to grow to $15.1 billion by 2017. (1)
  • The global drug market stands at about $880 Billion of which a significant portion is directly or indirectly intended for infectious disease treatment. (2)

To learn more about the assets available for sale in this portfolio:

Contact Dean Becker of ICAP Ocean Tomo at Dean.Becker@us.icap.com



About ICAP Ocean Tomo LLC

ICAP Ocean Tomo is the intellectual property brokerage division of ICAP and the world's premier patent auction firm.

About ICAP

ICAP is the world's premier interdealer broker and provider of post trade services. The Group matches buyers and sellers in the wholesale markets in interest rates, credit, commodities, foreign exchange, emerging markets, equities and equity derivatives through voice and electronic networks. ICAP plc was added to the FTSE 100 Index on 30 June 2006. For more information go to www.icap.com.

(1) http://www.eatg.org/eatg/Global-HIV-News/Pharma-Industry/HIV-drug-market-will-hit-15.1-billion-by-2017-but-competition-will-hot-up-too-New-research

(2) http://www.cphi-online.com/news/13036/Global+Pharmaceutical+Market+Growth+of+5-7%25+in+2011,+Reaching+$880+Billion.html


'/>"/>
SOURCE ICAP Ocean Tomo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The Ocean Becomes a Pipeline To A Cure for Cystic Fibrosis
2. Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing
3. Oceanside Pharmaceuticals Announces Launch of Librax(R) AG
4. ICAP Ocean Tomo Offers IP Portfolio of Near-Infrared Spectroscopy Technology
5. ICAP Ocean Tomo Offers for Sale Advanced Drug Formulation Technology From CyDex Pharmaceuticals Inc.
6. ICAP Ocean Tomo Offers for Sale IP Portfolio of Active Implants for Electromagnetic Bone and Tissue Regeneration in Orthopedics, Trauma, and Wound Care
7. Skin Lesion Identification System to Auction on November 11th at ICAP Ocean Tomos Fall 2010 Live IP Auction
8. ICAP Ocean Tomo to Auction 7 Exclusive Licenses from Lawrence Livermore National Laboratory at Fall Auction November 11th in Napa, California
9. Cutting Edge Nanotech Patents for Displays, Lighting, X-ray, Medical Imaging, and Diagnostics Available for Sale by ICAP Ocean Tomo
10. ICAP Ocean Tomo Announces Patents for a New and Safer Method of Treatment of Osteoporosis and Tumor Metastasis Using a Novel Zoledronic Acid Combination
11. ICAP Ocean Tomo Announces Advanced Techniques for Measuring Blood Pressure From Coherence L.L.C.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
(Date:6/23/2016)... Any dentist who has made an implant supported ... Many of them do not even offer this as a ... laboratory costs involved. And those who ARE able to offer ... high cost that the majority of today,s patients would not ... Zadeh , founder of Dental Evolutions Inc. and inventor of ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... that was developed to enhance the health of felines. The formula is all-natural and ... main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... "With 30 ... their specific project," said Christina Austin - CEO of Pixel Film Studios. , ... and all within Final Cut Pro X . Simply select a ProHand generator ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson has ... he has implemented orthobiologic procedures as a method for treating his patients. The ... first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons use ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
Breaking Medicine News(10 mins):